Cargando…

The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Background: Afatinib is a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been approved by the Food and Drug Administration for the treatment of advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. We performed a meta-analysis to asse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chi, Li, Yun, Ke, Li, Cao, Lejie, Fan, Pingsheng, Wu, Zhiwei, Wu, Quan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400820/ https://www.ncbi.nlm.nih.gov/pubmed/30854094 http://dx.doi.org/10.7150/jca.27528

Ejemplares similares

Suberoylanilide Hydroxamic Acid Treatment Reveals Crosstalks among Proteome, Ubiquitylome and Acetylome in Non-Small Cell Lung Cancer A549 Cell Line
por: Wu, Quan, et al.
Publicado: (2015)

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2017)

Afatinib in Non–Small Cell Lung Cancer
por: Wirth, Scott M.
Publicado: (2015)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam
por: Vu, Thanh Ha, et al.
Publicado: (2021)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Wang, Ziyu, et al.
Publicado: (2021)

Afatinib for the treatment of metastatic non-small cell lung cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
por: Wang, Shouzheng, et al.
Publicado: (2019)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà, Tiziana
Publicado: (2017)

Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non‐small cell lung cancer
por: Nie, Xin, et al.
Publicado: (2021)

Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence
por: Zhang, Lemeng, et al.
Publicado: (2021)

The Efficacy and Safety of Afatinib in Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Meta-Analysis
por: Jin, Hui, et al.
Publicado: (2023)

The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis
por: Zhou, Niya, et al.
Publicado: (2020)

Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2014)

Effects of Afatinib on Development of Non-Small-Cell Lung Cancer by Regulating Activity of Wnt/β-Catenin Signaling Pathway
por: Wu, Yue, et al.
Publicado: (2022)

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
por: Paz-Ares, L., et al.
Publicado: (2017)

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients
por: Wang, Lei-Yun, et al.
Publicado: (2018)

Transformation to small cell lung cancer after first-line afatinib treatment
por: Shiroyama, Takayuki, et al.
Publicado: (2018)

New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
por: Hirsh, Vera
Publicado: (2017)

Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib
por: Santos, Edgardo S, et al.
Publicado: (2020)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
por: Kang, Liping, et al.
Publicado: (2023)

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
por: Manca, Paolo, et al.
Publicado: (2017)

Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case report
por: Wu, Xiaokang, et al.
Publicado: (2021)

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021)

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
por: Wu, Yi-Long, et al.
Publicado: (2018)

Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
por: Liu, Zhefeng, et al.
Publicado: (2018)

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer
por: Lu, Shun, et al.
Publicado: (2022)

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
por: Huang, Chun-Yao, et al.
Publicado: (2023)

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
por: Lu, Shun, et al.
Publicado: (2018)

Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data
por: Hopkins, Ashley M., et al.
Publicado: (2019)

Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma
por: Yoo, Sang Hoon, et al.
Publicado: (2016)

Hypotension from afatinib in epidermal growth factor receptor-mutated non-small cell lung cancer: a case report and literature review
por: Tang, Zhiwei, et al.
Publicado: (2021)

Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report
por: Nie, Xin, et al.
Publicado: (2023)

Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report
por: Tu, Hai-Yan, et al.
Publicado: (2021)

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China
por: You, Ruxu, et al.
Publicado: (2019)

Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
por: Zhang, Shirong, et al.
Publicado: (2015)

Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report
por: Nishimura, Jun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jkgc06qunk0eif5od4jhsqkg0k